ReviewAnnual review of medicine2022
The Gut Microbiome and Inflammatory Bowel Diseases.
Review in Annual review of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 239 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
239 citing papers in PubMed, 7 syntheses or guidelines pooled it, 366 citations in OpenAlex.
- Engineered bacteria and engineered probiotics for intestinal disease therapy: a bibliometric and knowledge mapping analysis.Frontiers in microbiology · 2026Pooled it
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Pooled it
- Gut microbiota and ulcerative colitis: a bibliometric analysis of knowledge structure, research hotspots, and future directions.Frontiers in microbiology · 2026Pooled it
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Immunocytes Mediate the Effects of Gut Microbiome on Inflammatory Bowel Disease: Insights From a Mendelian Randomization Study.Mediators of inflammation · 2025Pooled it
- Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Modified Crohn's Disease Exclusion Diet and exclusive enteral nutrition (EEN) resolve oral dysbiosis in pediatric Crohn's disease: a prospective cohort study.Inflammatory bowel diseases · 2026Trial
- Mechanistic insights into fecal microbiota transplantation for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial.Journal of Crohn's & colitis · 2026Trial
- Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial.Nutrition journal · 2025Trial
- Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.Journal of Crohn's & colitis · 2024Trial
- Determinants of enteric hyperoxaluria in the SAMP1/YitFc mouse model of spontaneous ileitis.Gut microbes · 2026Article
- ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment.Drug delivery · 2026Article
- Bacterial cell envelope components of gut commensals: effects in host-microbe interaction.Annals of medicine · 2026Review
- Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential.Molecular biomedicine · 2026Review
- Docosahexaenoic acid alleviates DSS-induced colitis by regulating the gut microbiota and restoring the gut barrier.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Distinct Evolutionary Selection Patterns in Temperate and Filamentous Phages of Phocaeicola vulgatus in Health and IBD.Research square · 2026Article
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Integrated Multi-Omics Analysis of Antarctic Krill Oil in Alleviating DSS-Induced Colitis and Modulating Gut Microbiota in Mice.Marine drugs · 2026Article
- Review
179 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory bowel diseases (IBD) arise from a convergence of genetic risk, environmental factors, and gut microbiota, where each is necessary but not sufficient to cause disease. Emerging evidence supports a bidirectional relationship between disease progression and changes in microbiota membership and function. Thus, the study of the gut microbiome and host-microbe interactions should provide critical insights into disease pathogenesis as well as leads for developing microbiome-based diagnostics and interventions for IBD. In this article, we review the most recent advances in understanding the relationship between the gut microbiota and IBD and highlight the importance of going beyond establishing description and association to gain mechanistic insights into causes and consequences of IBD. The review aims to contextualize recent findings to form conceptional frameworks for understanding the etiopathogenesis of IBD and for the future development of microbiome-based diagnostics and interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.